Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.

Saved in:
Bibliographic Details
Title: Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.
Authors: Spreafico A; Department of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada., Couselo EM; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Irmisch A; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Bessa J; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Au-Yeung G; Department of Medical Oncology, Peter MacCallum Cancer Center and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia., Bechter O; Department of General Medical Oncology, Universitair Ziekenhuis (UZ), Leuven, Leuven, Belgium., Svane IM; National Center for Cancer Immune Therapy and Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Sanmamed MF; Department of Medical Oncology, Clínica Universidad de Navarra and Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Gambardella V; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain., McKean M; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, United States., Callahan M; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States., Dummer R; Department of Dermatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Klein C; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Umaña P; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Justies N; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Heil F; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Fahrni L; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Opolka-Hoffmann E; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Waldhauer I; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Bleul C; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Staack RF; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Karanikas V; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Fowler S; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Source: Frontiers in oncology [Front Oncol] 2024 Mar 21; Vol. 14, pp. 1346502. Date of Electronic Publication: 2024 Mar 21 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2024.1346502